Table 1

Clinico-pathological characteristics of the PDAC study cohort: correlation with Sirt1 expression
Characteristics All cases SIRT1 low SIRT1 high p-value
All cases
129 93 (72.1%) 36 (27.9%)
Age 0.401
≤65 years 65 (50.4%) 48 (73.8%) 17 (26.2%)
>65 years 64 (49.6%) 48 (70.3%) 17 (29.7%)
WHO stage 0.871
I 12 (9.3%) 9 (75%) 3 (25%)
IIA 17 (13.2%) 13 (76.5%) 4 (23.5%)
IIB 91 (70.5%) 66 (72.5%) 25 (27.5%)
III 5 (3.9%) 3 (60.0%) 2 (40.0%)
IV 4 (3.1%) 2 (50.0%) 2 (50.0%)
Tumour stage 0.793
T1 / / /
T2 24 (18.6%) 18 (75.0%) 6 (25.0%)
T3 100 (77.5%) 72 (72.0%) 28 (28.0%)
T4 5 (3.9%) 3 (60.0%) 2 (40.0%)
Nodal status 0.520
N0 31 (24.0%) 22 (71.0%) 9 (29.0%)
N1 98 (76.0%) 71 (72.4%) 27 (27.6%)
State of metastasis 0.310
M0 125 (96.9%) 91 (72.8%) 34 (27.2%)
M1 4 (3.1%) 2 (50.0%) 2 (50.0%)
Grade 0.001
G1 8 (6.2%) 6 (75.0%) 2 (25.0%)
G2 64 (49.6%) 55 (85.9%) 9 (14.1%)
G3 57 (44.2%) 32 (56.1%) 25 (43.9%)

Stenzinger et al.

Stenzinger et al. BMC Cancer 2013 13:450   doi:10.1186/1471-2407-13-450

Open Data